Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 4/20 | 0.51 |
| ▸ | PDE4A | P27815 | 3/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL1411222 | 0.94 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| SCHEMBL15282316 | 0.94 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| SCHEMBL29565987 | 0.94 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| SCHEMBL1411594 | 0.94 | PDE4D (0.52) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| Malic Acid SCHEMBL1411331 | 0.93 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| Gluconic Acid SCHEMBL1411256 | 0.93 | PDE4D (0.46) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| Bromide SCHEMBL1411707 | 0.93 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| Hydrochloric Acid SCHEMBL1411470 | 0.93 | PDE4D (0.51) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| Maleic Acid SCHEMBL15282211 | 0.92 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CALDH1A1 | |
| Fumaric Acid SCHEMBL1411694 | 0.92 | PDE4D (0.49) | PDE4DPDE4APDE4BPDE4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754218-B2 | Salts of 6-heterocycle substituted hexahydrophenanthridine derivatives | TAKEDA GMBH (DE) | 2014-06-17 | — | — | US | claimed |
| EP-2295423-B1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | TAKEDA GMBH (DE) | 2013-10-02 | — | — | EP | claimed |
| US-20130096152-A1 | NOVEL SALTS OF 6-HETEROCYCLE SUBSTITUTED HEXAHYDROPHENANTHRIDINE DERIVATIVES | NYCOMED GMBH (DE) | 2013-04-18 | — | — | US | claimed |
| EP-2295423-A1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | Nycomed GmbH (DE) | 2011-03-16 | — | — | EP | claimed |
| US-7718668-B2 | phosphodiesterase inhibitor; drug for respiratory system disorders | NYCOMED GMBH (DE) | 2010-05-18 | — | — | US | claimed |
| US-20080194587-A1 | phosphodiesterase inhibitor; drug for respiratory system disorders | NYCOMED GMBH (DE) | 2008-08-14 | — | — | US | claimed |
| US-9962377-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-9387205-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150352096-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-10 | — | — | US | disclosed |
| US-9149479-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20150119389-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| US-8883818-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| EP-2295423-A1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | Nycomed GmbH (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-20100190818-A1 | Novel salts of 6-heterocycle substituted hexahydrophenanthridine derivatives | NYCOMED GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
| EP-2189454-A1 | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | Nycomed GmbH (DE) | 2010-05-26 | — | — | EP | disclosed |
| US-20080194587-A1 | phosphodiesterase inhibitor; drug for respiratory system disorders | NYCOMED GMBH (DE) | 2008-08-14 | — | — | US | disclosed |
| US-20080167301-A1 | Respiratory system disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1723135-A1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005085225-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352096-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | PDE4D 5/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20150119389-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | PDE4D 4/4885PDE4A 1/4885PDE4B 2/4885 |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE12, PDE4B | PDE4D 5/4885PDE4A 1/4885PDE4B 3/4885 |
| US-20080167301-A1 | Respiratory system disorders | PDE4A, PDE4B, PDE12 | PDE4D 8/4885PDE4A 1/4885PDE4B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.